AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24899589 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-xyphoid pleural drain (Group SI)
Number of subjects: 68
Study 24899589 — intervention group
Group type: COMPARATOR
Intervention: Intercostal pleural drain (Group II)
Number of subjects: 68
Study 22435319 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% CPC mouthwash
Number of subjects: 60
Study 22435319 — intervention group
Group type: COMPARATOR
Intervention: Placebo mouthwash without CPC
Number of subjects: 60
Study 19665644 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 258
Study 19665644 — intervention group
Group type: COMPARATOR
Intervention: Sulfasalazine and hydroxychloroquine
Number of subjects: 258
Study 17417658 — intervention group
Group type: EXPERIMENTAL
Intervention: Live-attenuated varicella zoster vaccine
Number of subjects: 40
Study 15196111 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 36
Study 15196111 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 36
Study 15196111 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 36
Study 11772824 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075% ropivacaine with fentanyl 2 microg/mL
Number of subjects: 59
Study 11772824 — intervention group
Group type: COMPARATOR
Intervention: 0.075% bupivacaine with fentanyl 2 microg/mL
Number of subjects: 59
Study 11477910 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepared Rehmannia polysaccharide (PRP) associated with stanozolol
Number of subjects: 34
Study 11477910 — intervention group
Group type: COMPARATOR
Intervention: Stanozolol alone (Control)
Number of subjects: 34
Study 8597777 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopharmacy
Number of subjects: 200
Study 8597777 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy
Number of subjects: 200
Study 8597777 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups pooled
Number of subjects: 200
Study 8597777 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 200
Study 2540788 — intervention group
Group type: EXPERIMENTAL
Intervention: Four courses of cytotoxic chemotherapy (cyclophosphamide, vincristine, etoposide)
Number of subjects: 610
Study 2540788 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight courses of cytotoxic chemotherapy (cyclophosphamide, vincristine, etoposide)
Number of subjects: 610
Study 2540788 — intervention group
Group type: EXPERIMENTAL
Intervention: Four courses of chemotherapy followed by relapse chemotherapy (methotrexate and doxorubicin)
Number of subjects: 610
Study 2540788 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight courses of chemotherapy followed by relapse chemotherapy (methotrexate and doxorubicin)
Number of subjects: 610
Study 1078711 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (coronary bypass)
Number of subjects: 72
Study 1078711 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment (control)
Number of subjects: 72
Study 31960079 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 0
Study 31960079 — intervention group
Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 0
Study 31960079 — intervention group
Group type: COMPARATOR
Intervention: Abatacept
Number of subjects: 0
Study 31039587 — intervention group
Group type: EXPERIMENTAL
Intervention: Elastic wrapping (30 mm Hg) during dangling
Number of subjects: 30
Study 31039587 — intervention group
Group type: COMPARATOR
Intervention: Unwrapped dangling
Number of subjects: 30
Study 28177719 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyphenol beverage (1-1.5 L/day, approximately 400 mg of gallic acid equivalents per day)
Number of subjects: 277
Study 28177719 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage (without polyphenol enrichment)
Number of subjects: 277
Study 25116481 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-820836 (0.5 mg)
Number of subjects: 57
Study 25116481 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-820836 (0.1-4 mg)
Number of subjects: 57
Study 25116481 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 22915051 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mL PS yoghurt drink consumed 45 min prior to a solid meal
Number of subjects: 12
Study 22915051 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mL PS yoghurt drink consumed during a solid meal
Number of subjects: 12
Study 22915051 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mL PS yoghurt drink consumed 45 min after a solid meal
Number of subjects: 12
Study 21569487 — intervention group
Group type: EXPERIMENTAL
Intervention: Cleansing product (CP)
Number of subjects: 100
Study 21569487 — intervention group
Group type: COMPARATOR
Intervention: Water (W)
Number of subjects: 100
Study 19229417 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary veins isolation
Number of subjects: 42
Study 19229417 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Cox‐maze procedure
Number of subjects: 42
Study 19229417 — intervention group
Group type: COMPARATOR
Intervention: Control group (isolated mitral valve surgery)
Number of subjects: 42
Study 17135035 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol 2 mg/day
Number of subjects: 45
Study 17135035 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol 2 mg/day and norethisterone acetate 1 mg/day
Number of subjects: 45
Study 17135035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 14561021 — intervention group
Group type: EXPERIMENTAL
Intervention: IV/PO moxifloxacin 400 mg QD
Number of subjects: 376
Study 14561021 — intervention group
Group type: COMPARATOR
Intervention: IV/PO amoxicillin clavulanate 1200/625 mg TID +/- IV/PO clarithromycin 500 mg BID
Number of subjects: 376
Study 10908248 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis within 2 hours
Number of subjects: 2770
Study 10908248 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis within 2-4 hours
Number of subjects: 2770
Study 10908248 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis within 4-6 hours
Number of subjects: 2770
Study 10908248 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolysis within 6 hours
Number of subjects: 2770
Study 8635375 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (4 mg, qid)
Number of subjects: 0
Study 8635375 — intervention group
Group type: EXPERIMENTAL
Intervention: Cromolyn sodium (2 mg, qid)
Number of subjects: 0
Study 8635375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1727685 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.15 mg/kg i.v.)
Number of subjects: 21
Study 1727685 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.075 mg/kg i.v.)
Number of subjects: 21
Study 1727685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 6635761 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 15 mg/kg
Number of subjects: 85
Study 6635761 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 25 mg/kg
Number of subjects: 85
Study 6635761 — intervention group
Group type: EXPERIMENTAL
Intervention: Praziquantel 40 mg/kg
Number of subjects: 85
Study 31109849 — intervention group
Group type: EXPERIMENTAL
Intervention: Call center management for acute HAE attacks
Number of subjects: 100
Study 27425824 — intervention group
Group type: COMPARATOR
Intervention: NTP-CE (topical panthenol-containing emollient)
Number of subjects: 23
Study 25259540 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (3 d·wk⁻¹ for 40 min at 75%-85% HR reserve for 12 wk) in TL group
Number of subjects: 40
Study 25259540 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training (3 d·wk⁻¹ for 40 min at 75%-85% HR reserve for 12 wk) in TH group
Number of subjects: 40
Study 25259540 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training in TL group
Number of subjects: 40
Study 25259540 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic training in TL and TH groups
Number of subjects: 40
Study 22311659 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) applied (670 nm, 5 mW, 2 J/cm², 16 min, 5 days)
Number of subjects: 300
Study 22311659 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LLLT applied)
Number of subjects: 300
Study 21083596 — intervention group
Group type: EXPERIMENTAL
Intervention: rabeprazole 5 mg/day
Number of subjects: 288
Study 21083596 — intervention group
Group type: EXPERIMENTAL
Intervention: rabeprazole 10 mg/day
Number of subjects: 288
Study 21083596 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 288
Study 19137369 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-fibered microcoils
Number of subjects: 50
Study 19137369 — intervention group
Group type: COMPARATOR
Intervention: Amplatzer Vascular Plug II (AVP II)
Number of subjects: 50
Study 17470824 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (160 mg at week 0 and 80 mg at week 2)
Number of subjects: 325
Study 17470824 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 325
Study 17470824 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 325
Study 15887477 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in cardiovascular (CV) prevention during a CME meeting
Number of subjects: 343
Study 12000496 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with 1% benzyl benzoate and 1% tannic acid
Number of subjects: 30
Study 12000496 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 30
Study 12000496 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (first treatment)
Number of subjects: 30
Study 12000496 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (second treatment)
Number of subjects: 30
Study 12000496 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 30
Study 11382858 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral pallidotomy
Number of subjects: 23
Study 11382858 — intervention group
Group type: COMPARATOR
Intervention: Pre-operative condition
Number of subjects: 23
Study 7900630 — intervention group
Group type: EXPERIMENTAL
Intervention: Urodilatin (15 ng/kg/min for 10 hours)
Number of subjects: 12
Study 7900630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2729162 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose absorption in NIDDM subjects
Number of subjects: 21
Study 2729162 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine absorption in NIDDM subjects
Number of subjects: 21
Study 2729162 — intervention group
Group type: COMPARATOR
Intervention: Glucose absorption in healthy volunteers
Number of subjects: 21
Study 2729162 — intervention group
Group type: COMPARATOR
Intervention: Glycine absorption in healthy volunteers
Number of subjects: 21
Study 30034 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg Pindolol and 5 mg Clopamid (VKB 105)
Number of subjects: 678
Study 30034 — intervention group
Group type: EXPERIMENTAL
Intervention: VKB 105 (Pindolol and Clopamid)
Number of subjects: 678
Study 30034 — intervention group
Group type: EXPERIMENTAL
Intervention: VKB 105
Number of subjects: 678
Study 29980654 — intervention group
Group type: EXPERIMENTAL
Intervention: Pictorial health warnings (PHWs) placed on waterpipe devices
Number of subjects: 90
Study 28139100 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozurdex® implant (PRN group)
Number of subjects: 42
Study 28139100 — intervention group
Group type: COMPARATOR
Intervention: Ozurdex® implant (fixed group)
Number of subjects: 42
Study 25599540 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable spot scanning (VSS) ablation with the VISX STAR S4/IR platform
Number of subjects: 50
Study 25599540 — intervention group
Group type: COMPARATOR
Intervention: Wavefront-optimized (WFO) ablation profile with the WaveLight Allegretto Wave Eye‐Q platform
Number of subjects: 50
Study 23381501 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (immediate treatment)
Number of subjects: 64
Study 23381501 — intervention group
Group type: COMPARATOR
Intervention: Group B (no treatment for 3 months)
Number of subjects: 64
Study 23381501 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (long-term follow-up)
Number of subjects: 64
Study 22137084 — intervention group
Group type: COMPARATOR
Intervention: Basic support (nurse-led disease management program)
Number of subjects: 0
Study 22137084 — intervention group
Group type: COMPARATOR
Intervention: Intensive support (nurse-led disease management program)
Number of subjects: 0
Study 22137084 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (routine follow-up by a cardiologist)
Number of subjects: 0
Study 18669576 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 6 mg/day
Number of subjects: 42
Study 18669576 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 18206037 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary administration of anisodamine (200 microg/ml)
Number of subjects: 47
Study 18206037 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (Control group B)
Number of subjects: 47
Study 18206037 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary administration of anisodamine
Number of subjects: 47
Study 16004744 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision analysis
Number of subjects: 0
Study 16004744 — intervention group
Group type: EXPERIMENTAL
Intervention: Information video plus leaflet
Number of subjects: 0
Study 16004744 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 16004744 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups combined
Number of subjects: 0
Study 12402200 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin treatment
Number of subjects: 0
Study 9815053 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrin-17 (20 pmol. kg‐1. h‐1)
Number of subjects: 7
Study 9815053 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous famotidine (gastric acid inhibition)
Number of subjects: 7
Study 9815053 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 7
Study 8715223 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% propolis vaginal dressings applied for 10 consecutive days
Number of subjects: 0
Study 8715223 — intervention group
Group type: COMPARATOR
Intervention: Lugol daily dressings applied for 10 consecutive days
Number of subjects: 0
Study 2710561 — intervention group
Group type: EXPERIMENTAL
Intervention: gallamine
Number of subjects: 9
Study 2710561 — intervention group
Group type: EXPERIMENTAL
Intervention: lidocaine
Number of subjects: 9
Study 2710561 — intervention group
Group type: COMPARATOR
Intervention: normal saline
Number of subjects: 9
Study 340158 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 to 160 mg daily
Number of subjects: 10
Study 31366275 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Threat
Number of subjects: 146
Study 31366275 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Threat with Control
Number of subjects: 146
Study 31366275 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Threat with Control
Number of subjects: 146
Study 31366275 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 146
Study 31366275 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain-related fear
Number of subjects: 146
Study 30565426 — intervention group
Group type: EXPERIMENTAL
Intervention: β-alanine (BA) supplementation (12 g/day for 14 days)
Number of subjects: 19
Study 30565426 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 19
Study 30565426 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study 27286893 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept (2 mg)
Number of subjects: 32
Study 24996893 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspheric toric intraocular lens (Lentis L‐312T)
Number of subjects: 55
Study 24996893 — intervention group
Group type: COMPARATOR
Intervention: Aspheric nontoric intraocular lens (Lentis L‐312) with opposite clear corneal incision (OCCI)
Number of subjects: 55
Study 22832724 — intervention group
Group type: EXPERIMENTAL
Intervention: Circular plus ventral upward infiltration
Number of subjects: 89
Study 22832724 — intervention group
Group type: COMPARATOR
Intervention: Circular infiltration
Number of subjects: 89
Study 22832724 — intervention group
Group type: COMPARATOR
Intervention: Circular plus dorsal penile infiltration
Number of subjects: 89
Study 20499427 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1.5 microg/kg
Number of subjects: 40
Study 20499427 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 40
Study 17587273 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus casei rhamnosus Lcr35 (8 x 10(8) c.f.u./day)
Number of subjects: 45
Study 17587273 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium oxide (50 mg/kg/day)
Number of subjects: 45
Study 17587273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 15735561 — intervention group
Group type: EXPERIMENTAL
Intervention: Management in a Chest Pain Unit (CPU)
Number of subjects: 210
Study 15735561 — intervention group
Group type: COMPARATOR
Intervention: Conventional management in a Coronary Care Unit (CCU)
Number of subjects: 210
Study 11807965 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg hawthorn extract
Number of subjects: 36
Study 11807965 — intervention group
Group type: COMPARATOR
Intervention: 600 mg Mg
Number of subjects: 36
Study 11807965 — intervention group
Group type: COMPARATOR
Intervention: Combination of 600 mg Mg and 500 mg hawthorn extract
Number of subjects: 36
Study 11807965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 10417463 — intervention group
Group type: EXPERIMENTAL
Intervention: Cuffed oropharyngeal airway
Number of subjects: 20
Study 10417463 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway
Number of subjects: 20
Study 7762285 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 x 10(5) c.f.u. S. flexneri SFL1070
Number of subjects: 37
Study 7762285 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 x 10(7) c.f.u. S. flexneri SFL1070
Number of subjects: 37
Study 7762285 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 x 10(8) c.f.u. S. flexneri SFL1070
Number of subjects: 37
Study 7762285 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 x 10(9) c.f.u. S. flexneri SFL1070
Number of subjects: 37
Study 2283869 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit curriculum with designed activities and face-to-face teacher training
Number of subjects: 106
Study 2283869 — intervention group
Group type: COMPARATOR
Intervention: Other three smoking prevention programs (not specified)
Number of subjects: 106
Study 88753 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU chemotherapy (12 mg/kg daily for 4 days, then 6 mg/kg on alternate days, followed by 12 mg/kg weekly for 1 year)
Number of subjects: 299
Study 88753 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU chemotherapy
Number of subjects: 299
Study 31665323 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated SGTF (n = 125)
Number of subjects: 475
Study 31665323 — intervention group
Group type: EXPERIMENTAL
Intervention: Overtreated SGTF (n = 40)
Number of subjects: 475
Study 31665323 — intervention group
Group type: COMPARATOR
Intervention: Normal gestational thyroid function (GTF) (n = 246)
Number of subjects: 475
Study 31319398 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-dynamics-based intervention (8-week duration)
Number of subjects: 23
Study 31319398 — intervention group
Group type: COMPARATOR
Intervention: Individually supervised intervention (8-week duration)
Number of subjects: 23
Study 28399551 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for degenerative spondylolisthesis (DS) including instrumented fusion (72%), noninstrumented fusion (21%), and decompression alone (7%).
Number of subjects: 406
Study 28399551 — intervention group
Group type: COMPARATOR
Intervention: Nonreoperative patients
Number of subjects: 406
Study 25460264 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral Activation (5-day, 10-session protocol)
Number of subjects: 6
Study 25460264 — intervention group
Group type: COMPARATOR
Intervention: Baseline standard inpatient treatment
Number of subjects: 6
Study 23480783 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (n = 24)
Number of subjects: 62
Study 23480783 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (n = 20)
Number of subjects: 62
Study 23480783 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus Simvastatin (n = 18)
Number of subjects: 62
Study 23480783 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 62
Study 21692586 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Primary Nursing Care (CPNC)
Number of subjects: 470
Study 21692586 — intervention group
Group type: COMPARATOR
Intervention: Task-Centered Nursing Care (TCNC)
Number of subjects: 470
Study 18957487 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (3 or 6 mg/kg) plus methotrexate (MTX)
Number of subjects: 871
Study 18957487 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus methotrexate (MTX)
Number of subjects: 871
Study 16763547 — intervention group
Group type: EXPERIMENTAL
Intervention: [Nle4‐D‐Phe7]‐alpha‐melanocyte‐stimulating hormone (0.16 mg/kg, subcutaneous injection, 3 cycles of 10 days over 3 months)
Number of subjects: 65
Study 16763547 — intervention group
Group type: EXPERIMENTAL
Intervention: [Nle4‐D‐Phe7]‐alpha‐melanocyte‐stimulating hormone
Number of subjects: 65
Study 15123028 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam 0.2 mg/kg
Number of subjects: 70
Study 15123028 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diazepam 0.2 mg/kg
Number of subjects: 70
Study 15123028 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam
Number of subjects: 70
Study 15123028 — intervention group
Group type: COMPARATOR
Intervention: Intravenous diazepam
Number of subjects: 70
Study 11304782 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral capecitabine
Number of subjects: 605
Study 11304782 — intervention group
Group type: COMPARATOR
Intervention: Intravenous fluorouracil plus leucovorin (5‐FU/LV)
Number of subjects: 605